Women receiving silicone-gel breast implants have frequent complications like scarring or hardening breasts, and 20% or more of patients required implant removal within 10 years, the Food and Drug Administration said Wednesday.But the federal safety agency’s analysis didn’t show any unexpected or new safety concerns, and the implants will stay on the market. The conclusions were drawn in large part from studies done by the implants’ manufacturers, Allergan Inc. and Johnson & Johnson’s Mentor Worldwide unit.
